NeuSpera Medical
NeuSpera Medical is a San Jose-based medical device company that has developed ultra-miniaturized, battery-free implantable neuromodulation systems powered by its proprietary Mid-Field Powering Technology. Its FDA-approved iSNM system treats urinary urge incontinence, serving predominantly female adult patients and the urologists/urogynecologists who implant the device.
- Company typePrivate
- Founded2014
- HeadquartersSan Jose, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What NeuSpera Medical does
NeuSpera Medical, Inc. is a San Jose, California-based medical device company founded in 2014 (originally as Vivonda Medical) that designs, manufactures, and commercializes ultra-miniaturized implantable neuromodulation systems. Its core innovation is a proprietary Mid-Field Powering Technology that uses evanescent and propagating electromagnetic waves to wirelessly power and communicate with devices implanted up to 10cm deep in the body, enabling implants that are more than 100x smaller than traditional battery-powered neuromodulation devices. This architecture eliminates implanted batteries and the associated surgical complications while delivering efficacy comparable to traditional sacral neuromodulation (SNM).
The company's flagship product is the FDA-approved Integrated Sacral Neuromodulation (iSNM) System for urinary urge incontinence (UUI), approved in June 2025. The system consists of an ultra-miniaturized neurostimulator implanted near the sacral nerve, an external battery/therapy disc worn against the lower back, and a companion smartphone app for patient therapy adjustments, with an iPad-based clinician programmer for physician data access. NeuSpera also markets an FDA-cleared Peripheral Nerve Stimulation (PNS) System for chronic peripheral nerve pain, cleared in April 2023. The company serves adult patients (predominantly women) with UUI/OAB and the urologists and urogynecologists who implant the devices, targeting a market of approximately 300 million affected patients worldwide.
NeuSpera generates revenue through hardware sales of its implantable devices and recurring external battery/accessory components, distributed via direct physician engagement at hospital systems and specialty urology practices. The company is in the earliest stages of commercial launch following June 2025 FDA approval, and is building out its commercial organization under Chief Commercial Officer Steve Paul, with a leadership team recruited from Boston Scientific, Abbott, Coloplast, Ivantis, and Vertos Medical. The company has raised approximately $122 million in equity financing across angel, Series A through Series D rounds, with Vertex Ventures HC and Treo Ventures as repeated lead investors.
NeuSpera Medical firmographics
Firmographics- Name
- NeuSpera Medical
- Legal name
- Neuspera Medical, Inc.
- Website
- https://neuspera.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- NeuSpera Medical is a San Jose-based medical device company that has developed ultra-miniaturized, battery-free implantable neuromodulation systems powered by its proprietary Mid-Field Powering Technology. Its FDA-approved iSNM system treats urinary urge incontinence, serving predominantly female adult patients and the urologists/urogynecologists who implant the device.
- Ownership category
- akta.pro rank
NeuSpera Medical industry classification
Industry- Product category
- Implantable Neuromodulation Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)
- akta.pro secondary industry
- Pain Medicine (Interventional/Neuropathic Pain) (HLAKAIAM)
Keywords
Where NeuSpera Medical is headquartered
LocationHeadquarters
- HQ city
- San Jose
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
NeuSpera Medical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
Revenue model
- Implantable Medical Device Sales: Neuspera generates revenue from the sale of its implantable neurostimulation devices, including the FDA-approved iSNM system for urinary urge incontinence and the FDA-cleared peripheral nerve stimulation system. The company sells through direct engagement with healthcare providers and is building its commercial organization for full market launch.
- External Therapy Disc / Wearable Component Sales: The company sells external battery discs and accessories that work in conjunction with the implanted neurostimulator. These external components represent recurring consumable/accessory revenue for patients using the iSNM system.
Go-to-market motion3 records
Distribution channels2 records
Marketing channels6 records
NeuSpera Medical product offering
Product offeringCore offering
NeuSpera Medical designs, manufactures, and sells ultra-miniaturized implantable neuromodulation medical devices powered by its proprietary Mid-Field Powering Technology. The company's flagship product is the FDA-approved Integrated Sacral Neuromodulation (iSNM) system for urinary urge incontinence, which consists of an ultra-miniaturized implant, an external battery disc, a smartphone app, and an iPad-based clinician programmer. The company also offers an FDA-cleared Peripheral Nerve Stimulation (PNS) system for chronic nerve pain, and external wearable components that represent recurring accessory revenue.
Product overview
Neuspera Medical offers a portfolio of ultra-miniaturized neuromodulation devices powered by proprietary Mid-Field Powering Technology. The flagship product is the FDA-approved Integrated Sacral Neuromodulation (iSNM) System (also known as Nuvella during clinical trials) for treating urinary urge incontinence, which includes an implantable neurostimulator, external therapy disc, and companion smartphone application. The company also markets an FDA-cleared Peripheral Nerve Stimulation System for chronic pain. All products leverage wireless powering to eliminate the need for implanted batteries, significantly reducing device size and improving patient comfort compared to traditional neuromodulation systems.
Differentiator
Problem solved
Functional benefit
Brands
- Nuvella: First-generation sacral neuromodulation system name used during clinical trials; later branded as iSNM system
- iSNM System
- pSNM System
Products and services
- Neuspera Integrated Sacral Neuromodulation (iSNM) System FDA-approved integrated sacral neuromodulation system for urinary urge incontinence (UUI) consisting of an ultra-miniaturized neurostimulator implant (100x smaller than traditional devices), an external battery/therapy disc worn against the lower back, a smartphone application for therapy adjustments, and an iPad-based clinician programmer. Eliminates the need for implanted batteries while delivering gold-standard SNM efficacy. Designed for urologists and urogynecologists treating UUI patients who have failed medication management.
- Neuspera Peripheral Nerve Stimulation (PNS) System FDA-cleared first-of-its-kind leadless micro-implant system for chronic peripheral nerve pain management. 75x smaller than the smallest commercial implantable pulse generator, featuring a wireless platform with wearable transmitter and iPad-based clinician programmer. Designed for pain management physicians and specialists treating chronic peripheral nerve pain.
Quantifiable outcome
- 84.2% of implanted patients achieved at least 50% reduction in urgent leaks at 6 months (Phase II pivotal trial, 128 patients)
- +9 more outcomes
Companies that use NeuSpera Medical
Customer profileNamed customers6 records
Segments2 records
Ideal customer profiles2 records
NeuSpera Medical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
NeuSpera Medical partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered minor.
- MedTech InnovatorminorNeuspera was selected as one of 65 startups in the 2024 MedTech Innovator Cohort, providing visibility within the medtech ecosystem and access to mentorship, networking, and potential partnership opportunities with larger medtech companies.
- AdvaMedminorNeuspera Medical is a member of AdvaMed (Advanced Medical Technology Association), the leading trade association for the medical technology industry. The company and its employees follow applicable laws and regulations for the medical device industry.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
NeuSpera Medical competitors and assessment
Company assessmentBroad incumbents
- Medtronic: Medtronic is the incumbent market leader in sacral neuromodulation through its InterStim system, which has dominated the UUI/OAB market since 1997. Medtronic is Neuspera's primary direct competitor and the entrenched incumbent Neuspera must displace, with deep physician relationships and a multi-decade head start in SNM.
- Boston Scientific: Boston Scientific is a broad incumbent in neuromodulation (spinal cord stimulation, deep brain stimulation, dorsal root ganglion) and acquired Axonics in 2024 to enter the SNM market. Courtney Lane, Neuspera's VP of Clinical, Quality and Regulatory, previously led clinical affairs at Axonics and worked on Boston Scientific's DBS program.
- Abbott: Abbott is a broad neuromodulation incumbent with the Proclaim DRG system for dorsal root ganglion stimulation and other neurostimulation products. As a large diversified medical device company with extensive salesforce coverage, Abbott represents both a competitive threat and potential strategic acquirer for smaller neuromodulation players.
- Coloplast: Coloplast is a major urology medical device company offering continence care products and interventional urology solutions. Neuspera's former CEO Steffen Hovard previously led Coloplast Interventional Urology, and Coloplast competes broadly in the urology space where Neuspera is launching its iSNM system.
Direct peers
- Axonics Modulation Technologies: Axonics is Neuspera's most direct competitor, offering rechargeable sacral neuromodulation and peripheral nerve stimulation systems. Axonics was acquired by Boston Scientific, giving it the resources and salesforce to compete aggressively against Neuspera's battery-free iSNM system.
- Nevro: Nevro develops the Senza spinal cord stimulation system for chronic pain, competing in the neuromodulation space with Neuspera's PNS system. Both companies target the chronic pain market with neurostimulation devices, though Nevro focuses on spinal cord while Neuspera targets peripheral nerves.
Emerging players
- Inspire Medical Systems: Inspire Medical Systems is an emerging neuromodulation company with an FDA-approved hypoglossal nerve stimulation system for obstructive sleep apnea. Inspire represents a successful case study of a focused neuromodulation company scaling to commercial success, with a comparable sales motion to urology/specialty physician segments.
- Saluda Medical: Saluda Medical is an emerging neuromodulation company with the Evoke spinal cord stimulation system featuring closed-loop sensing technology. Saluda represents a next-generation neuromodulation competitor with innovative technology approaches similar to Neuspera's proprietary mid-field powering platform.
- SPR Therapeutics: SPR Therapeutics develops peripheral nerve stimulation systems for pain management, directly competing with Neuspera's FDA-cleared PNS system. SPR focuses on minimally-invasive PNS for acute and chronic pain, representing an emerging competitor in Neuspera's PNS indication.
- Nalu Medical: Nalu Medical develops a miniature peripheral nerve stimulation system for chronic pain, competing with Neuspera's PNS platform. Nalu's ultra-small implant and wearable battery form factor parallels Neuspera's miniaturization approach, making it a comparable emerging player in PNS.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
NeuSpera Medical social profiles
Digital presenceNeuSpera Medical compliance and trust
Trust signalCompliance2 records
NeuSpera Medical financial estimates
Financial estimateRevenue estimate
Valuation estimate
NeuSpera Medical leadership team
Management profileNumber of profiles
Profiles9 records
NeuSpera Medical funding detail
Funding detailFunding overview
Funding rounds7 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NeuSpera Medical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NeuSpera Medical
What does NeuSpera Medical do?
NeuSpera Medical designs, manufactures, and sells ultra-miniaturized implantable neuromodulation medical devices powered by its proprietary Mid-Field Powering Technology. The company's flagship product is the FDA-approved Integrated Sacral Neuromodulation (iSNM) system for urinary urge incontinence, which consists of an ultra-miniaturized implant, an external battery disc, a smartphone app, and an iPad-based clinician programmer. The company also offers an FDA-cleared Peripheral Nerve Stimulation (PNS) system for chronic nerve pain, and external wearable components that represent recurring accessory revenue.
Is NeuSpera Medical a public or private company?
NeuSpera Medical is a private company. It is classified as venture growth investor backed and is currently operating.
When was NeuSpera Medical founded?
NeuSpera Medical was founded in 2014. It employs 11 to 50 people.
Where is NeuSpera Medical based?
NeuSpera Medical is headquartered in San Jose, United States, in the North America region.
How does NeuSpera Medical make money?
Two revenue lines are on record. Implantable Medical Device Sales are the primary driver. The others are external Therapy Disc / Wearable Component Sales.
Who are NeuSpera Medical's main competitors?
Broad incumbents on record are Medtronic, Boston Scientific, Abbott and Coloplast. Direct peers are Axonics Modulation Technologies and Nevro. Emerging players are Inspire Medical Systems, Saluda Medical, SPR Therapeutics and Nalu Medical.
Does NeuSpera Medical have an API?
No public API is recorded for NeuSpera Medical.
What industry is NeuSpera Medical in?
NeuSpera Medical's product category is Implantable Neuromodulation Medical Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLAKAIAM, Pain Medicine (Interventional/Neuropathic Pain). Its NAICS code is 334510 and its SIC code is 3845.